These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: nm23-H1 protein immunoreactivity in cancers of the gallbladder, extrahepatic bile ducts and ampulla of Vater.
    Author: Lee CS, Pirdas-Zivcic A.
    Journal: Pathology; 1994 Oct; 26(4):448-52. PubMed ID: 7892048.
    Abstract:
    Immunohistochemical expression of the nm23-H1 protein was investigated in carcinoma of the gallbladder (n = 13), common bile duct (n = 5) and ampulla of Vater (n = 7) using the monoclonal antibody, NM 301 (Molecular Oncology Inc.). This was compared with cases of chronic cholecystitis (n = 11) and preneoplastic lesions of the gallbladder (n = 4) and ampulla (n = 3). Absent or weak nm23-H1 protein immunoreactivity was found in most (67%) of the poorly differentiated adenocarcinomas of the gallbladder and in half of the cases of moderately differentiated adenocarcinomas. The difference in nm23-H1 protein immunostaining between gallbladder carcinoma and chronic cholecystitis was statistically significant (p = 0.0022; X2 test). Significant correlation was found between prolonged patient survival periods and nm23-H1 immunoreactivity in gallbladder carcinomas (R = 0.687, p = 0.01, linear regression analysis; r = 0.652, p = 0.016, Spearman's rank test). Most of the gallbladder dysplasias and adenomas had no reduction in nm23-H1 protein immunoreactivity. All common bile duct carcinomas, most (67%) ampullary carcinomas in situ and some (43%) ampullary carcinomas had moderate to strong nm23-H1 immunostaining. In summary, low nm23-H1 protein immunoreactivity was found more frequently in gallbladder carcinomas than in chronic cholecystitis and was associated with reduced patient survival. The differences in nm23-H1 protein immunoreactivity in common bile duct and ampullary carcinomas suggest that these tumors have a different molecular origin to gallbladder cancers.
    [Abstract] [Full Text] [Related] [New Search]